ERBB2 and neoplasm: The combination of Neratinib and T-DM1 in the same lung human tumor xenograft model (PDXS) with ERBB2 amplification and mutation (S310F) has a more significant and lasting effect than that of T-DM1 alone in inducing tumor regression (61).